预计发行认购股份所得款项净额(扣除开支后)约为1285.83万港元，而每股认购股份的净价格约为3.93港 元。预计发行可转换票据所得款项净额(扣除开支后)约为5133万港元，而每股转换股份的净价格约为4.9 港元。公司拟以下列方式运用所得款项净额总额：最高约641.88万港元(占所得款项净额总额最高约 10%)将用作一般营运资金;及最高约5776.95万港元(占所得款项净额总额最高约90%)将用于把握日后可 能出现的潜在投资机会，探索加密货币投资及Web 3.0的机会，及/或收购比特币等数字资产。于本公告 日期，除在公开市场收购比特币外，集团并无发现任何具体的潜在投资机会或目标。 认购股份相当于经发行认购股份扩大后的股份总数的约0.81%(假设自本公告日期起及直至发行认购股份 完成日期的股份总数概无其他变动)。按初始转换价每股转换股份5港元计算，因悉数行使可转换票据附 带的转换权而将予配发及发行的转换股份合共为1047.55万股，相当于经发行认购股份及转换股份扩大 后的已发行股份总数的约2.53%(假设除发行认购股份外，自本公告日期起直至可转换票据按初始转换价 获悉数转换完成，股份总数概无其他变动)。认购价每 ...

陆控ADR美股盘后涨0.38%，该公司港交所公告宣布Yong Suk Cho（赵容奭）将继续担任CEO，Alston Zhu辞去 CFO、任命Tongzhuan Xi（席通专）为新的CFO。 陆金所控股有限公司 NYSE: LU ! 概览 对比 财务信息 謝永林先生 市场概况 > 陆金所控股有限公司 2.62 USD + 关注 +0.15 (6.07%) ↑ 今天 收盘时间: 4月23日 GMT-4 下午5:10 · 免责声明 盘后价 2.63 +0.010 (0.38%) 6 个月 YTD 1 天 5天 1 个月 1年 5年 最大 2.70 2.65 2.60 2.55 昨日 2.50 收盘价 2.47 2.45 上午10:00 下午12:00 下午2:00 下午4:00 下午6:00 下午8:00 22.71亿 开盘 2.49 52 周高点 市值 4.94 2.00 最高 2.66 市盈率 52 周低点 時得所控股 JIFAX Lufax Holding Ltd 陆金所控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號：6623) (紐交所股票代碼：LU) 董事名單及其角色和職能 陆金所控股有限公 ...

IBM(IBM.N)：宏观经济环境不稳定；维持全年收入增长和自由现金流预期不变。 ...

Core Viewpoint - The head-to-head trial results of Iwosimab (PD-1/VEGF dual antibody) against the PD-1 therapy from BeiGene demonstrate significant clinical benefits, marking a milestone in the treatment of squamous non-small cell lung cancer (sq-NSCLC) [1][2][3] Group 1: Clinical Trial Results - Iwosimab combined with chemotherapy showed strong positive results compared to BeiGene's Tislelizumab combined with chemotherapy in a pivotal Phase III trial (AK112-306/HARMONi-6) for advanced sq-NSCLC [1] - The trial results indicate statistically significant benefits and major clinical advantages, which are expected to enhance treatment options for sq-NSCLC patients [2][3] - Iwosimab has previously demonstrated a doubling of median progression-free survival (mPFS) in a head-to-head trial against Merck's Keytruda (Pembrolizumab) [2] Group 2: Market Impact and Company Performance - Following the announcement of the trial results, Kangfang Biopharma's stock surged over 10%, reaching a historical high of 100 HKD per share, with a cumulative increase of over 40% in recent times [2] - The sales figures for Tislelizumab are projected to be 3.806 billion CNY in 2023 and 4.467 billion CNY in 2024, indicating its status as a leading domestic PD-1 therapy [2] Group 3: Industry Trends and Innovations - The Chinese innovative drug sector is increasingly taking the lead in lung cancer treatment, with a notable shift from "follower" to "leader" status in various therapeutic areas [6] - The latest National Medical Insurance directory includes 12 new drugs for lung cancer treatment, reflecting the growing innovation in the Chinese pharmaceutical industry [6] - The overall five-year survival rate for late-stage lung cancer patients in China has improved from 5% during the chemotherapy era to 20%-30% currently, although it still lags behind the overall cancer survival rate of 43% [6] Group 4: Future Prospects - Kangfang Biopharma is expected to release international multi-center Phase III clinical data for Iwosimab in 2025, which could lead to a submission for FDA approval if results are positive [8] - The company emphasizes the importance of head-to-head trials to establish the clinical value of new therapies against existing standards [4][5]

Core Viewpoint - The article highlights Li Ning's efforts in promoting sustainable practices within the sportswear industry, showcasing a comprehensive approach to environmental responsibility through innovative materials and production processes [2][4][10]. Group 1: Environmental Initiatives - Li Ning is presenting its "full-chain" environmental products, including bio-based yarn shoes, waterless dyeing, and recycled plastic uniforms, aiming to create a clear green path from raw materials to finished products [2][3]. - The company has developed a complete lifecycle of green products, utilizing materials like castor oil-based bio-yarn and recycled plastic bottles, indicating a shift from isolated attempts to a systematic approach [3][4]. - Li Ning's commitment to sustainability is reflected in its collaboration with research institutions to develop fully biodegradable shoes, demonstrating a long-term vision for eco-friendly products [3][4]. Group 2: Market Position and Challenges - The global sportswear market is increasingly focused on sustainability, with brands like Nike and Adidas leading the way, while Chinese brands like Li Ning are still in the early stages of this transition [2][3]. - Li Ning's Vice President, Song Chuntao, emphasizes that environmental materials do not compromise performance, citing the elasticity and durability of their bio-yarn used in high-performance running shoes [6][10]. - The company aims to balance the rising costs of sustainable materials with product performance, asserting that they will not raise prices solely based on environmental claims [7][10]. Group 3: Consumer Trends and Corporate Responsibility - Consumer attitudes are shifting towards sustainability, with 46% of consumers willing to pay a premium for sustainable products, indicating a growing market for eco-friendly options [10]. - Li Ning has integrated ESG (Environmental, Social, and Governance) considerations into its corporate strategy, establishing an ESG management committee to oversee sustainability efforts [10]. - The company recognizes that sustainable development is not just a choice but a necessary challenge for the industry, with leading companies playing a crucial role in advancing these initiatives [10].

Group 1 - The Nasdaq China Golden Dragon Index has increased by 4.3% [1] - XPeng Motors (XPEV.N) has risen by 8% [1] - Kingsoft Cloud (KC.O) has gained 9% [1] - GDS Holdings (GDS.O) has seen a rise of 7% [1]

Core Viewpoint - Lingxiong Technology (02436.HK) has reported a record revenue of approximately 2.372 billion RMB for 2024, marking a year-on-year growth of about 32.3%, showcasing its resilience in a challenging macroeconomic environment [1] Group 1: Financial Performance - Revenue for 2024 reached approximately 2.372 billion RMB, a year-on-year increase of 32.3% [1] - Gross profit increased by 33% to approximately 196 million RMB [1] - Adjusted EBITDA grew by 17.6% to approximately 283 million RMB [1] - Equipment recycling business revenue rose by 42.7% to approximately 1.836 billion RMB [2] - Equipment subscription service revenue increased by 9.1% to approximately 380 million RMB [2] - Total equipment subscription volume grew by 7.5% to approximately 6.176 million units [2] Group 2: Business Model and Strategy - The DaaS business model demonstrates strong resilience and operational excellence, allowing the company to navigate complex economic cycles [1][3] - Lingxiong Technology focuses on enhancing customer service and experience, which is crucial for maintaining its competitive edge [1][3] - The company has built a closed-loop DaaS ecosystem that generates significant synergies and supports its subscription services [3] Group 3: Digital Transformation and Innovation - Lingxiong Technology is advancing its digital transformation, enhancing operational efficiency through a fully integrated digital chain [4] - The launch of the Xiaoxiong Ubao APP improves internal operational efficiency by facilitating customer maintenance actions [4] - The integration of AI technology is expected to significantly enhance customer service efficiency and quality [4][5] Group 4: Market Outlook and Growth Potential - The DaaS industry is experiencing a favorable window of opportunity due to increasing enterprise demand and supportive government policies [6][7] - The market penetration rate for DaaS services is projected to rise from approximately 5% to 10% over the next five years [7] - Lingxiong Technology is well-positioned to benefit from the anticipated growth in the DaaS market, with significant potential for revenue and profit expansion [7]

根据国际糖尿病联盟数据显示，2021年全球成年糖尿病患者达5.37亿人，患病率高达10.5%，其中，中 国患者达1.41亿人，占全球总数的26.2%。SGLT-2抑制剂作为新型作用机制降糖药物，市场规模增长迅 速，根据华创医药的研究报告指出，2024年前三季度，SGLT-2抑制剂在中国大陆的销售额接近80亿 元。而2024年达格列净销售额高达约70亿元，行业专家也表示达格列净目前保持着20%–30%的年度增 长率。 达格列净片是惠升生物继脯氨酸加格列净片(1类创新药)、恩格列净片后获得上市批准的第三个SGLT-2 抑制剂类药物。达格列净片的获批，不仅进一步完善了本集团及惠升生物在糖尿病治疗领域的产品佈 局，并可为糖尿病患者提供更优的治疗选择，帮助更多患者实现更好的血糖管理，降低并发症风险，从 而全面提升患者的生活品质和长期预后，切实造福广大糖尿病患者群体。 智通财经APP讯，四环医药(00460)发布公告，集团旗下非全资附属公司惠升生物制药股份有限公司研发 的达格列净片已获中华人民共和国国家药品监督管理局颁发的药品注册批件，用于2型糖尿病成人患 者，视同通过仿制药品质和疗效一致性评价。 达格列净片为全球首款获 ...

Core Viewpoint - The company is expected to continue optimizing its product structure in 2024, with significant results from its new energy sector and an increase in revenue contribution from safety protection composite materials, highlighting economies of scale [1][2]. Financial Performance - In 2024, the company achieved a revenue of 1.057 billion yuan, a year-on-year increase of 14.04%, and a net profit attributable to shareholders of 217 million yuan, up 31.18% year-on-year [2][3]. - For Q1 2025, the company reported a revenue of 259 million yuan, an 18.00% increase year-on-year, while the net profit attributable to shareholders was 52 million yuan, a 22.69% increase year-on-year [2][3]. Profit Growth Drivers - The main reasons for the net profit growth in 2024 include: 1. Continuous optimization of product structure, leading to increased sales of high-value-added and innovative products, which improved overall sales prices and gross margins [3]. 2. Successful results from the new energy sector, with an increased revenue share from safety protection composite materials, showcasing economies of scale [3]. 3. High conversion rate of R&D investments, forming a diversified business matrix that enhances synergy and increases market share of core products [3]. 4. Significant cost reduction and efficiency improvement through supply chain management and lower procurement prices for key materials [3]. 5. Improved financial structure with reduced financial expenses and increased returns from cash management [3]. Product Performance - In 2024, revenue from high-temperature mica insulation materials was 727 million yuan, a year-on-year increase of 4.65%, with a gross margin of 38.17% [3]. - Revenue from new energy safety protection composite materials reached 220 million yuan, a substantial year-on-year increase of 81.41%, although the gross margin decreased to 33.38% [3]. - Revenue from fiberglass cloth was 106 million yuan, a slight year-on-year increase of 0.87%, with a gross margin of 23.43% [3].